Dihexa for PCOS (PMOS) Brain Fog & Polyendocrine Metabolic Ovarian Syndrome Cognitive Dysfunction: Hyperandrogenism, Insulin Resistance, BDNF, GLP-1, the May 2026 PMOS Rename, NICE PCOS Guideline (Dec 2026) & the UK Review

Around 3 million UK women live with PCOS (~10% of women of reproductive age) on NHS England figures, with up to 70% of cases undiagnosed and a meaningful diagnostic delay; globally the condition affects approximately 170 million women. The condition has experienced its biggest scientific and policy upheaval in nearly a century. On 12 May 2026, The Lancet published the global consensus paper renaming PCOS to PMOS — Polyendocrine Metabolic Ovarian Syndrome — the result of a 14-year initiative led by the Endocrine Society, the International Androgen Excess and PCOS Society, Verity (the UK PCOS Charity) and 53 other patient and clinical organisations across 56 institutions; the renaming was supported by 86% of patients and 71% of clinicians in surveys of more than 14,300 respondents. On 31 January 2024, Heather Huddleston, Eleni Jaswa and colleagues at UCSF published in Neurology the first long-running prospective cohort analysis of PCOS and midlife brain health: in 907 women followed for 30 years in the CARDIA study (Coronary Artery Risk Development in Young Adults), the 66 women (7.1%) meeting PCOS criteria scored approximately 11% lower on attention (Stroop), lower on verbal learning and memory (RAVLT) and lower on category fluency, and in the imaging subset of 291 women, the 25 with PCOS showed reduced total white-matter fractional anisotropy on diffusion tensor imaging (DTI) MRI — a marker of compromised white-matter microstructure. The 2016 Rees et al. Journal of Clinical Endocrinology and Metabolism paper had already reported reduced white-matter microstructure and lower cognitive function in young women with PCOS; the cognitive trajectory in PCOS appears to diverge decades before midlife. On 9 December 2026, NICE is due to publish GID-NG10436, the first UK NICE PCOS guideline — the most consequential UK PCOS policy event in a generation. Until then, UK practice is anchored by the 2023 International Evidence-Based PCOS Guideline by Teede, Tay, Joham, Misso, Costello, Stener-Victorin and colleagues at Monash, endorsed by ESHRE / ASRM / Endocrine Society / NIH / Verity. GLP-1 receptor agonist prescribing in PCOS has risen 7-fold from 2.4% in 2021 to 17.6% in 2025 on Truveta data, driven by semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro); the UK Semaglutide vs Metformin in PCOS randomised controlled trial is registered with the Health Research Authority. The mechanistic story converges on a hyperandrogenism / insulin-resistance / chronic-low-grade-inflammation triple axis, with a particularly important downstream finding: BDNF is elevated, not deficient, in PCOS — the Russo, Tartaglione 2012 paper documented serum and follicular-fluid BDNF approximately 2x healthy controls; the 2026 Frontiers in Nutrition adolescent PCOS paper formalised serum BDNF as a neuro-immunometabolic marker; the 2025 ACS Chemical Neuroscience paper formally proposed BDNF dysregulation as the bridge between PCOS and autism spectrum disorder cognitive phenotypes. Against this backdrop, does Dihexa have anything to offer the UK’s 3 million women with PCOS / PMOS — or is there a real theoretical risk that further BDNF / TrkB synaptic plasticity, augmented by an HGF/c-Met activator in a condition where HGF is already biologically active in the ovary, could consolidate rather than relieve the central-sensitisation cognition pathology and worsen ovarian biology? This rigorous 2026 UK review covers what is actually known, what is speculation, and where the evidence is genuinely absent. Readers may also want to read the closely related Dihexa for Endometriosis Brain Fog review (significant PCOS / endometriosis comorbidity), the Dihexa for Menopause Brain Fog review (PCOS women transition to menopause differently), the Dihexa & GLP-1 (Ozempic / Wegovy / Mounjaro) review (the most relevant medication-class context), the Dihexa for Diabetes Brain Fog review (PCOS women have ~4x T2DM risk), the Dihexa for Sleep Apnea Brain Fog review (PCOS women have ~5x OSA risk), the Dihexa for Anxiety & Stress review (~41-69% anxiety comorbidity), the Dihexa for Depression & Mood review (~37% depression comorbidity) and the Dihexa for Autism Spectrum Disorder review (the BDNF-bridge hypothesis).

PCOS / PMOS in the UK in 2026: Scale, Burden & Why Brain Fog Matters

PCOS — from 12 May 2026 increasingly referred to as PMOS (Polyendocrine Metabolic Ovarian Syndrome) — is the commonest endocrine disorder in women of reproductive age. NHS England estimates a population prevalence of approximately 10% of women of reproductive age in the UK, equating to roughly 3 million women. Globally the condition affects approximately 170 million women. Critically, up to 70% of cases are undiagnosed — one of the largest unmet diagnostic loads in women’s health, comparable in scale to endometriosis and exceeded only by menopause in numerical reach.

PCOS is the leading cause of anovulatory infertility worldwide. It carries a markedly elevated risk profile for downstream metabolic and reproductive disease: Type 2 diabetes mellitus risk is approximately 4-fold elevated relative to age-matched women without PCOS; cardiovascular disease risk is elevated; obstructive sleep apnea risk is approximately 5-fold elevated; non-alcoholic fatty liver disease (NAFLD / MASLD) is overrepresented; endometrial cancer risk is approximately 3-fold elevated due to chronic anovulation and unopposed oestrogen exposure; and depression and anxiety comorbidity is substantial (see section 6). The condition also has substantial psychosocial morbidity from hirsutism, androgenetic alopecia, acne and weight gain.

Brain fog and cognitive symptoms in PCOS — until very recently invisible to mainstream guidelines — are now formally documented. The 31 January 2024 Huddleston et al. paper in Neurology from UCSF, using the long-running CARDIA (Coronary Artery Risk Development in Young Adults) cohort followed over 30 years, was the first prospective long-term study to demonstrate that women with PCOS perform approximately 11% lower on attention (Stroop test), lower on verbal learning and memory (RAVLT) and lower on category fluency by midlife, with the imaging subset showing reduced total white-matter fractional anisotropy on DTI MRI — a marker of compromised white-matter microstructural integrity. The earlier 2016 Rees, Udiawar et al. Journal of Clinical Endocrinology and Metabolism paper had already shown reduced white-matter microstructure and lower cognitive function in young women with PCOS — suggesting the trajectory diverges decades before clinically apparent midlife decline.

May 2026: The PMOS Global Consensus Rename in The Lancet

On 12 May 2026, The Lancet published 'Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process' — the culmination of a 14-year initiative led by the Endocrine Society, the International Androgen Excess and PCOS Society, Verity (the UK PCOS Charity) and 53 other patient, clinical and research organisations across 56 institutions.

Why the rename was needed

The acronym PCOS (polycystic ovary syndrome) has been clinically dominant since the 1990s, derived ultimately from the 1935 Stein-Leventhal description of a polyfollicular ovarian morphology and the 1988 Polson ultrasound paper that documented polycystic ovaries in around 22% of normal women. The term has long been recognised as a misnomer: the “cysts” described are not true cysts but arrested antral follicles visible on ultrasound; up to 30% of PCOS patients do not have polycystic-appearing ovaries at all; the term obscures the central metabolic and endocrine pathology (insulin resistance, hyperandrogenism, dyslipidaemia, glucose intolerance, NAFLD risk) that drives long-term morbidity; and clinicians and patients have long described the diagnostic delay and dismissal that the name has contributed to.

The 14-year consensus process

The rename was the product of a multi-year structured consultation. Surveys were issued to over 14,300 respondents across patients with PCOS and multidisciplinary clinicians from all world regions; 86% of patients and 71% of clinicians supported moving away from PCOS to a more biologically accurate symptom-based name. Shortlisting and validation iterations across the 56-organisation steering group converged on Polyendocrine Metabolic Ovarian Syndrome (PMOS) as best reflecting (a) the endocrine multi-axis disruption (insulin / HPO axis / adrenal axis / thyroid susceptibility), (b) the central metabolic phenotype, and (c) the ovarian site of the diagnostic morphological signature.

Implications for UK clinical practice

The rename has immediate implications across nomenclature, coding, patient communication and research:

• SNOMED CT and ICD-11 updates are expected over 2026-2028; clinicians should anticipate dual nomenclature in the interim. NHS Digital coding decisions are pending.
• The forthcoming NICE PCOS guideline GID-NG10436 (publication 9 December 2026) is expected to integrate the rename and use a PCOS / PMOS dual term, given publication is 7 months after the rename consensus.
• UK patient advocacy — Verity, PCWHS (Polycystic Ovary Women’s Health Society) — is rolling out PMOS-aware messaging.
• Research naming conventions in trials registered before 12 May 2026 will retain PCOS; trials registered subsequently are expected to use PCOS / PMOS.
• Continuity of patient lookup and education: most patients will continue to search and identify as “PCOS” for at least the next decade; clinicians should use both terms in communication.

The May 2026 rename is also strategically aligned with the April 2026 Women’s Health Strategy for England, which includes 117 action points and an explicit pledge to "eliminate the diagnostic odyssey facing women" with conditions including endometriosis, fibroids and PCOS. The strategy mandates a single gynaecological referral point, ringfenced funding to reduce gynaecology waiting lists, and integration of women’s health into GP training. Reducing the ~70% PCOS undiagnosed rate is a key strategy outcome.

Rotterdam Criteria, AMH & the 2023 International Evidence-Based PCOS Guideline

PCOS diagnosis has evolved across three major frameworks: NIH 1990 (hyperandrogenism + oligo/anovulation), Rotterdam 2003 (any 2 of 3: clinical or biochemical hyperandrogenism; oligo/anovulation; polycystic ovarian morphology), and the 2006 Androgen Excess and PCOS Society criteria (hyperandrogenism + one of the other two). The Rotterdam 2003 criteria are the most widely used and define four phenotypes (A, B, C, D) based on which criteria are met.

The 2023 International Evidence-Based PCOS Guideline (Teede et al.)

The most consequential pre-NICE document is the 2023 update of the International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome by Helena Teede, Chau Thien Tay, Anju Joham, Marie Misso, Melanie Gibson-Helm, Michael Costello, Elisabet Stener-Victorin and colleagues at Monash University and the Monash Centre for Health Research and Implementation. The guideline was developed by a multidisciplinary international panel with endorsement from ESHRE, ASRM, NIH, the Endocrine Society and Verity (UK PCOS Charity).

Key 2023 updates include:

• AMH (anti-Mullerian hormone) as a Rotterdam diagnostic alternative in adults: serum AMH > an age-specific cut-off can substitute for ultrasound polycystic ovarian morphology, increasing accessibility and reducing diagnostic delay. AMH is less invasive than transvaginal ultrasound and avoids the false-positive issue in adolescents and the immediately post-pubertal period.
• Adolescent diagnostic caution: ultrasound morphology and irregular menses are common in normal adolescents; the guideline recommends conservative diagnosis with serial re-evaluation.
• Letrozole as first-line ovulation induction for anovulatory infertility — preferred over clomifene per multiple RCTs showing higher live-birth rates.
• Metformin recommended for adolescents with PCOS where insulin resistance / weight management is a priority.
• GLP-1 receptor agonists increasingly used off-label in obese PCOS patients for weight management; the 2023 guideline acknowledges emerging evidence and the rapid practice change.
• Inositol (myo-inositol + D-chiro-inositol, classically in the 40:1 ratio of products like Inofolic) formally listed as experimental therapy — possible metabolic benefit, limited clinical benefit for ovulation, hirsutism or weight, low risk of harm.
• Cardiometabolic screening at diagnosis and at regular intervals: HbA1c or fasting glucose (OGTT in higher-risk), lipid profile, blood pressure, BMI / waist circumference, NAFLD screening.
• Mental-health screening at diagnosis for depression, anxiety, eating disorder and body-image concerns — recognising the substantial psychiatric comorbidity.
• Endometrial protection in chronic anovulatory cycles — cyclical progestogen or Mirena IUS to prevent unopposed-oestrogen endometrial hyperplasia.
• Long-term cancer risk discussion: ~3-fold elevated endometrial cancer risk, no clearly elevated breast or ovarian cancer risk.

Biochemistry: testosterone, free androgen index, SHBG, 11-oxygenated androgens, AMH, LH/FSH

The standard biochemistry panel includes: total testosterone (often elevated, but assay sensitivity is critical — LC-MS/MS is gold standard); SHBG (sex hormone binding globulin, typically reduced); free androgen index (testosterone / SHBG); DHEAS (adrenal androgen, may be elevated); AMH (elevated 2-3x healthy controls due to increased granulosa-cell production from arrested follicles); LH (often elevated with an LH:FSH ratio of 2:1 or 3:1); fasting glucose / HbA1c / oral glucose tolerance test; fasting insulin (HOMA-IR > ~2.5 cutoff); lipid profile; 17-OH progesterone to exclude non-classical congenital adrenal hyperplasia; TSH to exclude thyroid disease; prolactin to exclude prolactinoma; and 24-hour urinary cortisol or overnight dexamethasone suppression in clinically suspicious cases to exclude Cushing’s syndrome.

The emerging interest in 11-oxygenated C19 androgens (especially 11-ketotestosterone) following the Turcu et al. 2017 PNAS paper is particularly relevant in PCOS: these are predominantly adrenal-derived androgens that have similar receptor activity to testosterone, are not routinely measured in conventional panels, and may be the dominant pathological androgen in many PCOS phenotypes. UK availability of 11-keto-testosterone assays remains limited.

The PCOS Brain Fog Evidence: From Patient Reports to Neurology

For at least a decade, online PCOS patient communities have reported brain fog, mental fatigue, memory difficulty and word-finding problems as a defining feature of living with the condition. Until recently the clinical literature was sparse. That has now changed:

January 2024: The Huddleston CARDIA Neurology Paper

The 31 January 2024 paper by Heather Huddleston, Eleni Jaswa, Marcelle Cedars and colleagues from UCSF — using the long-running CARDIA cohort (Coronary Artery Risk Development in Young Adults), one of the longest-running multicentre US prospective studies — is the strongest single piece of human evidence to date for PCOS-associated cognitive decline. Of 1,163 women in the CARDIA Women’s Study, 907 completed cognitive testing at year 30 (mean age 54.7), with 66 (7.1%) meeting PCOS criteria. Adjusted analyses showed the PCOS group performed:

• ~11% lower on Stroop — a measure of selective attention and cognitive control.
• Significantly lower on Rey Auditory Verbal Learning Test (RAVLT) long-delay recall — episodic memory.
• Significantly lower on category fluency — verbal-semantic abilities and processing.

In the imaging subset of 291 women (25 with PCOS, 8.5%), brain MRI with diffusion tensor imaging showed significantly reduced total white-matter fractional anisotropy — an MRI-derived marker of axonal density and myelin integrity — in the PCOS group. This is the structural correlate of the cognitive performance findings and signals that white-matter microstructural disruption may be a substrate of PCOS midlife cognitive change.

2016: The Rees White-Matter Paper in Young Women

The 2016 Rees, Udiawar, Berlot, Jones, O'Sullivan Journal of Clinical Endocrinology and Metabolism paper looked at young women with PCOS using DTI MRI, and reported reduced white-matter microstructural integrity and lower cognitive function — a near-perfect prequel to the Huddleston midlife findings. The implication of reading these two papers together is significant: PCOS-associated white-matter and cognitive divergence appears to begin in the reproductive years and accumulate across decades, rather than being a midlife-onset phenomenon. This has implications for early metabolic-axis intervention.

2020: Resting-State fMRI Cerebral Activity Changes

The 2020 PMC7758505 resting-state functional MRI study reported altered regional cerebral activity in women with PCOS — consistent with the white-matter microstructural changes and providing a functional-imaging correlate.

2021: Acne, Hirsutism, Anxiety, Depression and Cognitive Performance

The 2021 PMC7778752 cross-sectional study reported lower cognitive performance correlating with hyperandrogenism (acne, hirsutism, biochemical androgen excess) and the burden of anxiety and depression — the psychosocial-and-biological intersection that the 2024 CARDIA paper formalised at the population scale.

2022: Metabolic Syndrome, Cognition and White Matter in CARDIA

The 2022 CARDIA metabolic syndrome paper (PMC9339689) documented that metabolic syndrome (the constellation of central obesity, hypertension, dyslipidaemia and insulin resistance that overlaps with PCOS) is associated with lower cognitive performance and reduced white-matter integrity at midlife. PCOS women have markedly elevated rates of metabolic syndrome (35-80% insulin resistance prevalence; 95% in those with obesity); this is one mechanistic pathway underlying the PCOS midlife cognitive findings.

Adolescent & Young-Adult Evidence

The 2024 Frontiers in Endocrinology systematic review and meta-analysis on depression, anxiety and self-esteem in adolescent girls with PCOS documented elevated rates of all three across multiple cohorts — the precursor mental-health pattern that contributes to cognitive trajectory.

The Triple-Axis Mechanism: Hyperandrogenism, Insulin Resistance & Chronic Low-Grade Inflammation — with BDNF as the Central Paradox

1. Hyperandrogenism & the Androgen-Brain Axis

Hyperandrogenism is the most distinctive PCOS feature. Elevated testosterone, free testosterone, free androgen index, DHEAS and 11-oxygenated androgens (especially 11-ketotestosterone, identified as the predominant adrenal-derived bioactive androgen in PCOS per the Turcu 2017 PNAS paper) act centrally on hippocampal, prefrontal-cortical and limbic androgen receptors. Animal and human studies suggest hyperandrogenism in females is associated with impaired hippocampal-dependent memory consolidation, altered prefrontal-cortex executive function and altered amygdala emotional processing. Hyperandrogenism also drives PCOS-associated hirsutism, acne and androgenetic alopecia which independently contribute to psychological distress, depression and anxiety — themselves cognitive load.

2. Insulin Resistance, Hyperinsulinaemia & Hippocampal Insulin Signalling

Insulin resistance affects 35-80% of women with PCOS, rising to 95% in those with obesity. Hyperinsulinaemia drives down SHBG production by the liver, increasing free testosterone and aggravating hyperandrogenism. Insulin resistance also operates centrally: hippocampal insulin signalling is critical for memory consolidation and synaptic plasticity (see the broader story in our Dihexa for Diabetes Brain Fog review), and PCOS-associated insulin resistance is mechanistically convergent with the Type 2 diabetes brain-fog literature. Hyperinsulinaemia also disrupts theca-cell androgen synthesis (CYP17A1 hyperresponsiveness) and granulosa-cell function. The 4-fold elevated risk of Type 2 diabetes in PCOS is a downstream amplifier of all these effects.

3. Chronic Low-Grade Inflammation

PCOS is now well-established as a state of chronic low-grade systemic inflammation: elevated hsCRP, IL-6, TNF-alpha, IL-1-beta and innate-immunity activation. Adipose tissue dysfunction (where present), gut dysbiosis (active 2024-2025 research area), advanced glycation end-products (AGE / RAGE signalling), NLRP3 inflammasome activation, and elevated chemerin (linked to both ovarian and HGF biology) all contribute. The same peripheral cytokine pattern crosses the blood-brain barrier and activates microglia — the sickness-behaviour neuroinflammation model that underlies long COVID brain fog, fibro fog, ME/CFS cognitive dysfunction and diabetes brain fog.

4. The Central BDNF Paradox in PCOS

BDNF is elevated — not deficient — in PCOS, and that single fact is the most important biological observation for any synaptogenic-peptide claim in this indication.

• Russo, Tartaglione, Mateev et al. (2012), Gynecological Endocrinology: PCOS serum and follicular-fluid BDNF approximately 2x healthy controls.
• 2026 Frontiers in Nutrition adolescent PCOS paper: serum BDNF is a neuro-immunometabolic marker integrating inflammation (IL-1-beta, MDA, T-AOC), dietary and oxidative parameters.
• 2025 ACS Chemical Neuroscience: BDNF dysregulation as a neurobiological bridge between PCOS and ASD — both conditions share an elevated-but-dysregulated BDNF signature.
• 2022 PMC9571561: moderate aerobic exercise rescues follicular dysfunction via BDNF-mediated anti-apoptotic signalling in PCOS mouse models — BDNF is biologically active in PCOS ovaries, not just brain.

This is the same elevated-BDNF pattern seen in endometriosis (Wu Hu Liang 2022), migraine (Tanure 2010) and fibromyalgia (Polli 2020). The central uncomfortable question for Dihexa in PCOS / PMOS is the same one that recurs across these conditions: if BDNF is already chronically elevated and is part of a dysregulated signalling complex, pharmacologically pushing BDNF/TrkB signalling further with a synaptogenic peptide is the wrong pharmacological direction. Read the broader BDNF analysis in our Dihexa & BDNF review.

5. HGF/c-Met in the PCOS Ovary: A Second Directionality Concern

HGF (hepatocyte growth factor) and its receptor c-Met have well-documented roles in ovarian biology: granulosa-cell HGF production, theca-cell interactions, follicular development and atresia, and endometrial receptivity. The Parrott 1994 work and subsequent papers established HGF as a paracrine factor in folliculogenesis. PCOS ovaries demonstrate aberrant follicular arrest, theca-cell hyperactivation, elevated AMH 2-3x healthy controls, stromal hyperplasia and altered granulosa biology. While direct HGF measurements in PCOS ovaries are limited, the convergent literature on chemerin (which interacts with HGF) and on inflammatory cytokine spillover suggests HGF/c-Met signalling in PCOS is at least dysregulated. Dihexa’s headline mechanism — HGF/c-Met activation — therefore has a second theoretical concern beyond the central BDNF directionality issue: pharmacologically augmenting HGF/c-Met signalling in a PCOS ovary may worsen rather than improve ovarian biology. This is mechanistic speculation rather than tested fact; there is no Dihexa-in-PCOS data.

Mental-Health, Sleep, Metabolic & Reproductive Comorbidity

PCOS rarely exists in isolation. The 2024 systematic review and meta-analysis literature documents:

• Depression: ~37% pooled prevalence across populations (95% CI 29-44%); higher in obese subgroups; 5-fold elevated suicide attempt risk (Cesta et al. Karolinska, 2016).
• Anxiety: 41-69% depending on instrument (Hospital Anxiety and Depression Scale ~41.5%, Hamilton Anxiety Scale ~69%, Self-rating Anxiety Scale ~32.4%); social phobia and generalised anxiety prominent.
• Eating disorders (binge eating, bulimia, food-control behaviours) elevated.
• Body-image distress, self-esteem reduction, sexual-function impairment particularly in the hirsutism / acne / androgenetic alopecia subgroup.
• Obstructive sleep apnea (OSA): ~5-fold elevated risk — sleep fragmentation independently contributes to cognitive dysfunction; see our sleep apnea review.
• Type 2 diabetes: ~4-fold elevated risk — see diabetes brain fog review.
• NAFLD / MASLD overrepresented — cognitive impact via insulin resistance and hepatic-encephalopathy spectrum at extreme.
• Endometrial cancer: ~3-fold elevated risk from chronic anovulation and unopposed oestrogen exposure.
• Cardiovascular risk: elevated coronary heart disease and stroke incidence.
• Endometriosis overlap in a substantial minority; see our endometriosis review.
• Migraine overrepresented; see our migraine review.
• Long COVID brain fog overlap, both via shared metabolic risk and via post-viral persistent symptoms; see our long COVID review.

The cognitive burden of PCOS is therefore multiply determined: hyperandrogenism / insulin resistance / inflammation triple-axis plus depression/anxiety load plus sleep fragmentation plus polypharmacy (combined oral contraceptive, metformin, spironolactone, antidepressant, GLP-1, hypnotics in a substantial minority). Addressing the modifiable contributors — lifestyle, weight, sleep, depression/anxiety, OSA — is the appropriate first step before any nootropic consideration.

The 2026 UK Treatment Landscape & the NICE PCOS Guideline GID-NG10436

UK PCOS management until 9 December 2026 is anchored by the 2023 International Evidence-Based PCOS Guideline (Teede et al., Monash), the RCOG green-top guideline 33 on long-term consequences of PCOS and individual NICE clinical knowledge summaries. The pathway has five priorities, stratified by the woman’s clinical concern:

1. Lifestyle & Weight Management

Lifestyle is foundational across all PCOS phenotypes. Weight loss of 5-10% body weight in those with elevated BMI is associated with restoration of menstrual regularity, ovulation, fertility and metabolic improvement in a substantial proportion of patients. Mediterranean-style diet, exercise, sleep hygiene and smoking cessation are core. Exercise has documented BDNF-modulatory effects in PCOS ovarian biology (PMC9571561) and in brain. The 2024 evidence supports both endurance and resistance training.

2. Menstrual Irregularity, Hirsutism & Acne

First-line is the combined oral contraceptive (COC), preferred low-androgenic preparations: levonorgestrel (Microgynon), norethisterone, or drospirenone (Yasmin) — the latter with mild anti-mineralocorticoid effect. Second-line for refractory hirsutism is co-cyprindiol (Dianette — ethinylestradiol + cyproterone acetate), prescribed under acne / hirsutism indication, with the recognised increased VTE risk advice. Spironolactone 100-200mg/day off-licence is a widely-used anti-androgen for hirsutism, often combined with COC for contraceptive cover (essential due to anti-androgen teratogenicity). Finasteride (5-alpha-reductase inhibitor) and topical eflornithine (Vaniqa) are additional options for facial hirsutism. Topical retinoids and benzoyl peroxide for acne, with oral antibiotic or isotretinoin escalation per dermatology pathways. Mirena IUS provides endometrial protection in anovulatory cycles. Cyclical progestogen (medroxyprogesterone, dydrogesterone, norethisterone) for endometrial protection is the alternative.

3. Insulin Resistance & Metabolic Risk

Metformin 500mg-2g/day remains first-line for insulin resistance, weight management and metabolic risk, with evidence for menstrual restoration and modest weight benefit. Inositol (myo-inositol + D-chiro-inositol in the 40:1 ratio of products like Inofolic) is widely used in private and primary-care settings; the 2023 Teede guideline lists it as experimental with low risk of harm and limited clinical benefit for ovulation, hirsutism or weight.

The single biggest practice change in PCOS in 2024-2026 has been the rise of GLP-1 receptor agonist therapy. Truveta data show prescribing of semaglutide / tirzepatide in women with PCOS rose 7-fold from 2.4% in 2021 to 17.6% in 2025. Semaglutide (Wegovy, Ozempic) is licensed in the UK for obesity (Wegovy) and Type 2 diabetes (Ozempic) and is increasingly used off-label or via obesity-pathway eligibility in PCOS with elevated BMI. Tirzepatide (Mounjaro) — a dual GLP-1 / GIP agonist — is now widely accessed via NHS NICE TA1026 obesity rollout from June 2025 and the April 2026 QOF GP-contract integration. The UK HRA-registered Semaglutide vs Metformin in PCOS RCT is in progress. The November 2025 EVOKE / EVOKE+ Phase 3 failure of semaglutide in mild Alzheimer’s disease tempered enthusiasm for direct CNS GLP-1 effects, but the metabolic-substrate logic in PCOS remains strong. For the full GLP-1 brain analysis, see our Dihexa & GLP-1 (Ozempic / Wegovy / Mounjaro) review.

Bariatric surgery is an option in carefully selected severely obese PCOS patients with metabolic complications. Statin therapy is indicated where cardiovascular risk meets QRISK thresholds.

4. Anovulatory Infertility

For women trying to conceive, the 2023 international guideline recommends letrozole 2.5mg as first-line ovulation induction (preferred over clomifene per multiple RCTs showing higher live-birth rates). Clomifene remains widely used historically. Gonadotrophin (FSH) ovulation induction is second-line. Laparoscopic ovarian drilling (LOD) at BSGE-accredited centres remains an option in selected patients. IVF per NICE fertility pathways and CCG eligibility is the final step. Metformin can improve ovulation in some PCOS patients and is sometimes combined with ovulation induction. Pre-conception weight loss substantially improves fertility outcomes. Important: GLP-1 therapy is contraindicated for women actively trying to conceive; recommended washout is at least 2 months before conception for semaglutide and tirzepatide.

5. Long-Term Screening & Mental Health

The 2023 guideline mandates long-term screening: HbA1c or fasting glucose every 1-3 years (more frequent in higher-risk subgroups); lipid profile and blood pressure; NAFLD/MASLD screening with LFTs and abdominal ultrasound where indicated; endometrial protection in chronic anovulatory cycles; OSA screening in symptomatic patients (see sleep apnea review); and mental-health screening at diagnosis and at intervals for depression, anxiety, eating disorder and quality-of-life impact.

The NICE PCOS Guideline GID-NG10436 (Publication 9 December 2026)

NICE is developing the first UK NICE PCOS guideline — GID-NG10436, Polycystic ovary syndrome: assessment and management, publication scheduled for 9 December 2026. The guideline is expected to (a) integrate the 12 May 2026 PMOS rename in nomenclature, (b) align UK practice with the 2023 international evidence-based guideline, (c) clarify NHS-commissioned vs private pathway responsibilities, (d) standardise the diagnostic algorithm including AMH as a Rotterdam alternative, (e) address the ~70% diagnostic delay rate consistent with the April 2026 Women’s Health Strategy “eliminate the diagnostic odyssey” pledge, (f) formalise mental-health screening and long-term metabolic surveillance, and (g) define the role of GLP-1 receptor agonists in PCOS where obesity and metabolic risk coexist. Brain fog and cognitive symptoms are not currently confirmed as named endpoints in the draft scope, but stakeholder consultation has raised this. NICE PCOS guideline development is open to inputs via the PCOS NICE consultation page; Verity has been actively involved.

The April 2026 Women’s Health Strategy for England

On 14 April 2026 the UK Government published the renewed Women’s Health Strategy for England with 117 action points and an explicit pledge to "eliminate the diagnostic odyssey facing women" — explicitly naming endometriosis, fibroids and PCOS as priority conditions. The strategy mandates a single gynaecological referral point, ringfenced funding to reduce gynaecology waiting lists, an audit of women’s health services, integration of women’s health into GP training, and a commitment to reduce diagnostic delay across the named conditions.

Where Could Dihexa Theoretically Fit in PCOS / PMOS Biology?

The honest summary: in PCOS / PMOS, every primary disease axis where Dihexa has a mechanistic story is one where the directionality of effect is questionable rather than supportive. The dominant cognitive pathology is metabolic / inflammatory, the dominant peripheral biomarker is elevated BDNF, the ovarian pathology involves HGF/c-Met biology — each axis points to Dihexa augmenting a system already in a dysregulated state. There is no clean BDNF-deficit case to motivate augmentation, and there is a strong indicated pathway (metabolic correction, hormonal management, GLP-1 where appropriate, mental-health support) that already addresses the dominant drivers.

PCOS-Specific Risks & Theoretical Concerns

Beyond the generic risks in the Dihexa side-effects review, PCOS / PMOS-specific concerns include: elevated-BDNF directionality (augmenting a BDNF system already in hyperdrive — the central directionality concern); ovarian HGF / c-Met activity (HGF is a paracrine factor in folliculogenesis; pharmacologically augmenting in a PCOS ovary with aberrant follicular arrest, theca-cell hyperactivation and elevated AMH may worsen ovarian biology, anovulation, androgen synthesis or fertility); hyperandrogenism interaction (testosterone and DHT interact with hippocampal androgen receptors; an unstudied peptide adding to an already-dysregulated androgen-brain axis is uncharted); fertility, pregnancy and IVF interaction (PCOS affects reproductive-age women, many actively trying to conceive, pregnant, or in fertility treatment; Dihexa teratogenicity is unstudied; pregnancy and lactation are strict contraindications; interaction with letrozole, clomifene, gonadotrophin, IVF protocols is unstudied; HGF/c-Met has documented endometrial-receptivity biology); endometrial cancer risk (PCOS women have ~3-fold elevated endometrial cancer risk from chronic anovulation; c-Met is an oncogenic driver in multiple tumours, including endometrial; pharmacologically augmenting HGF/c-Met in this risk context is concerning); insulin resistance and GLP-1 interaction (many patients are on metformin and increasingly semaglutide or tirzepatide; pharmacokinetic and pharmacodynamic interactions are unstudied; note also that GLP-1 therapies have pancreatitis, gastroparesis, biliary, retinopathy and thyroid-C-cell concerns); combined oral contraceptive and anti-androgen interaction (most PCOS patients are on ethinylestradiol, drospirenone, levonorgestrel, cyproterone, spironolactone, finasteride; all interactions are unstudied); adolescent and paediatric safety (PCOS now diagnosed earlier; Dihexa in under-18s has no safety data; the 2026 Frontiers Nutrition adolescent paper documents disturbed BDNF biology that augmenting could worsen); central sensitisation overlap in comorbid migraine, fibromyalgia, IBS and depression (directionality concerns from those reviews apply); delayed appropriate care (any time spent on an unproven peptide is time not spent on lifestyle, metformin, GLP-1, anti-androgens, fertility care, screening, mental-health support, and the December 2026 NICE pathway). The directionality concerns here are not idle: they map onto the central scientific anchors of the condition.

Fosgonimeton (ATH-1017) & the HGF/c-Met Clinical Track Record in Women’s Health

Fosgonimeton (ATH-1017), Athira Pharma’s injectable HGF / c-Met positive modulator developed as the most rigorously studied HGF-pathway molecule in humans, has never been tested in any PCOS, PMOS, hyperandrogenism, anovulation or polycystic-ovary population. The LIFT-AD Phase 3 trial in mild-to-moderate Alzheimer’s disease failed to meet its primary cognitive endpoint in 2024; SHAPE in Parkinson’s dementia and LIFT-DLB were discontinued. The most relevant inference for PCOS: even in central-nervous-system indications where BDNF-deficit and HGF-modulation rationale was cleanest, the human evidence is unsupportive. Extrapolating from no signal in Alzheimer’s to a hypothetical signal in PCOS — a condition with elevated rather than deficient BDNF, with active ovarian HGF/c-Met biology, with no precedent — is not scientifically defensible.

Adjacent UK Research & the Verity / RCOG / NICE Ecosystem

UK PCOS research is anchored by Verity (the UK PCOS Charity, founded 1997), the only dedicated UK PCOS charity, which provides patient support, drives advocacy, and has been a key partner in the 12 May 2026 PMOS rename consensus. RCOG sets the gynaecology and obstetrics framework. The British Thyroid Association and the Society for Endocrinology support the endocrine context. The 2023 Fertility Family PCOS Awareness Survey documented current UK patient experience. Major UK academic centres for PCOS research include Imperial College London (Stephen Franks and collaborators — the leading UK PCOS clinical academic for over 30 years), University of Birmingham (Wiebke Arlt and colleagues — pioneering work on 11-oxygenated androgens), University of Manchester, Cardiff University (Aled Rees, lead author of the 2016 white-matter paper), and University of Oxford. UK PCOS clinical trials in progress can be searched on NIHR Be Part of Research and on ClinicalTrials.gov. There is no Dihexa-related trial registered in any PCOS or PMOS indication anywhere in the world.

June 2026 News Roundup: PCOS / PMOS

The 2025-2026 PCOS news landscape has been unusually busy. The headline events relevant to UK patients and clinicians:

• 12 May 2026: The Lancet publishes global consensus rename of PCOS to PMOS; STAT, TIME, AJMC and the Endocrine Society cover the announcement.
• April 2026: Renewed Women’s Health Strategy for England with 117 action points, naming PCOS as a priority condition for diagnostic odyssey elimination.
• Throughout 2026: NICE PCOS guideline GID-NG10436 stakeholder consultation; publication 9 December 2026.
• 2026 Frontiers in Nutrition: Serum BDNF as integrative neuro-immunometabolic marker in adolescent PCOS.
• 2025 ACS Chemical Neuroscience: BDNF-Dysregulation as a Neurobiological Bridge between PCOS and ASD.
• Truveta 2025 report: 7-fold rise in GLP-1 prescribing in women with PCOS from 2.4% (2021) to 17.6% (2025).
• 2024 January, Neurology: Huddleston et al. CARDIA midlife PCOS cognition paper.
• 2023: International Evidence-Based PCOS Guideline (Teede et al.) update — the dominant pre-NICE document.

Bottom Line

The PCOS / PMOS brain fog story is finally in the open. The 2024 Huddleston CARDIA paper provided the first long-term prospective evidence of midlife cognitive decline in PCOS, the 2016 Rees paper had already shown the white-matter changes start in young adulthood, the 2026 PMOS rename in The Lancet has reframed the entire conceptual model around the metabolic-endocrine pathology, the NICE PCOS guideline GID-NG10436 is due 9 December 2026 and will be the most consequential UK policy event in a generation, and the 7-fold rise in GLP-1 prescribing has changed clinical practice faster than guidelines can track.

None of this changes the position on Dihexa. The 2026 evidence base in PCOS / PMOS does not support synaptogenic peptide use: BDNF is elevated rather than deficient, ovarian HGF/c-Met biology is itself active and aberrant, the dominant cognitive pathology is metabolic and inflammatory and addressed through the evidence-based metabolic / hormonal / mental-health pathway, and there is no human Dihexa trial in any PCOS-related population anywhere in the world. The directionality concerns are not minor. The clinical cousin fosgonimeton has failed in cleaner CNS indications. The 2026 UK pathway is the 2023 Teede international guideline transitioning to NICE GID-NG10436 in December 2026 with Verity-led patient advocacy — not an unproven research peptide.

Cannot be recommended in 2026.

Closely Related Reviews on This Site

• Dihexa for Endometriosis Brain Fog — significant PCOS / endometriosis comorbidity and the BDNF-elevated-in-pelvis paradox.
• Dihexa for Menopause Brain Fog — PCOS women transition to menopause differently; HRT considerations.
• Dihexa & GLP-1 (Ozempic / Wegovy / Mounjaro) — the most relevant medication-class context for PCOS in 2026.
• Dihexa for Diabetes Brain Fog — PCOS women have ~4x T2DM risk; insulin signalling overlap.
• Dihexa for Sleep Apnea Brain Fog — ~5x OSA prevalence in PCOS.
• Dihexa for Anxiety & Stress — 41-69% PCOS anxiety prevalence.
• Dihexa for Depression & Mood — 37% PCOS depression prevalence.
• Dihexa for Autism Spectrum Disorder — the 2025 ACS Chem Neuro BDNF-as-bridge-between-PCOS-and-ASD paper.
• Dihexa for Migraine — PCOS women have elevated migraine prevalence.
• Dihexa for Fibromyalgia & Fibro Fog — shared central-sensitisation and BDNF biology.
• Dihexa for Long COVID Brain Fog — shared microglial activation paradigm.
• Dihexa for MCI & Brain Aging — midlife cognitive trajectory in PCOS.
• Dihexa & BDNF — the BDNF biology that anchors the directionality concern.
• Fosgonimeton (ATH-1017) — the closest HGF-pathway clinical evidence.
• Mechanism of Action — HGF/c-Met biology at the molecular level.
• Side Effects & Risks — oncogenicity, fertility and pregnancy contraindications.
• Claimed Benefits — what is and isn’t mechanistically defensible.
• Research & Studies — the human evidence base.

Key References & External Sources

1. Teede HJ, Tay CT, Joham AE et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. DOI link.
2. Huddleston HG, Jaswa EG, Lin J, Cedars MI et al. (31 January 2024). Associations of Polycystic Ovary Syndrome With Indicators of Brain Health at Midlife in the CARDIA Cohort. Neurology. Neurology DOI | PMC11383880 | PMID 38295344.
3. Rees DA, Udiawar M, Berlot R, Jones DK, O'Sullivan MJ (2016). White Matter Microstructure and Cognitive Function in Young Women With Polycystic Ovary Syndrome. JCEM. PMC4701841.
4. Teede HJ, Tay CT, Joham AE et al. (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS. JCEM & Fertility and Sterility. JCEM full text.
5. NICE GID-NG10436 (publication 9 December 2026). Polycystic ovary syndrome: assessment and management. NICE In Development.
6. Russo N, Tartaglione AM, Mateev S et al. (2012). Polycystic ovary syndrome: brain-derived neurotrophic factor plasma and follicular fluid levels. Gynecological Endocrinology. PMID 22420627.
7. Serum BDNF as integrative neuro-immunometabolic marker in adolescent PCOS (2026). Frontiers in Nutrition. Frontiers full text.
8. BDNF-Dysregulation as a Neurobiological Bridge between PCOS and Autism Spectrum Disorder (2025). ACS Chemical Neuroscience. ACS Chem Neuro.
9. Moderate Aerobic Exercise Regulates Follicular Dysfunction by Initiating BDNF Anti-Apoptotic Signaling in PCOS (2022). PMC9571561.
10. Tang Y et al. (2020). Changes in Resting-State Cerebral Activity in Women With Polycystic Ovary Syndrome: A Functional MR Imaging Study. PMC7758505.
11. The Metabolic Syndrome Is Associated With Lower Cognitive Performance and Reduced White Matter Integrity in Midlife: The CARDIA Study (2022). PMC9339689.
12. Truveta. Rising use of GLP-1 medications among women with PCOS (2025). Truveta report.
13. Health Research Authority. Semaglutide vs Metformin in PCOS (UK RCT). HRA summary.
14. Verity — The UK PCOS Charity. Verity homepage | News & Research.
15. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 33 — Long-term consequences of polycystic ovary syndrome. RCOG Green-Top 33.
16. Department of Health and Social Care. Women’s Health Strategy for England (April 2026). GOV.UK.
17. Benoist CC, Wright JW, Zhu M, Appleyard SM, Wayman GA, Harding JW (2014). HGF/c-Met-dependent procognitive and synaptogenic effects of angiotensin IV-derived peptides. JPET. PMID 24403718.
18. Wright JW, Harding JW (2015). The Brain HGF/c-Met Receptor System: A New Target for Alzheimer’s Disease. JAD. PMID 25711386.
19. The Endocrine Society on the PMOS rename. Endocrine Society announcement.
20. NHS Polycystic Ovary Syndrome. NHS Conditions A-Z.

This is an educational research review of Dihexa in the context of PCOS / PMOS brain fog. Nothing on this page is a substitute for personalised medical advice. PCOS / PMOS is a serious endocrine and metabolic condition with significant long-term cardiometabolic, reproductive and mental-health implications. Suspected PCOS should be assessed by a GP and managed under the 2023 International Evidence-Based PCOS Guideline transitioning to the NICE PCOS guideline GID-NG10436 due 9 December 2026, with endocrinology / gynaecology / fertility / mental-health input as indicated. See our full legal disclaimer.